Tue, Apr 16, 2024
Volume 9, Issue 2 (12-2022)
vacres 2022, 9(2): 18-23 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
ghazavi A, khaki M, Mosayebi G, Keshavarzian N, Navabi P, Ganji A. Efficacy of Two Vaccine Platforms against SARS-CoV-2. vacres 2022; 9 (2) :18-23
URL: http://vacres.pasteur.ac.ir/article-1-312-en.html
URL: http://vacres.pasteur.ac.ir/article-1-312-en.html
Department of Immunology, School of Medicine, Arak University of Medical Sciences, Arak, Iran
Abstract: (1017 Views)
Introduction: Several vaccine platforms have been designed to elicit an effective immune response against SARS-CoV-2. This study was aimed to evaluate the humoral immune response in Iranian people vaccinated with both inactivated virus vaccines and vector vaccine platforms. Methods: The study enrolled 360 vaccinated individuals with inactivated virus vaccines (BBIBP-CorV and Covaxin) and vector vaccine platforms (AstraZeneca and Sputnik V). Serum samples were collected for each volunteer on days 14 to 21 after vaccination, and anti–SARS-CoV-2 spike receptor-binding domain (RBD) IgG concentrations were analyzed by ELISA. Results: Higher antibody titers were observed in participants vaccinated with vector vaccines compared with those immunized with inactivated virus, especially in subjects who received two doses of AstraZeneca. (AstraZeneca: 204.19 U/mL [95% CI, 175.5-232.2] vs. Sputnik V :114.67 U/mL [95% CI, 99.54-129.8]; P = 0.007). It was also observed that antibody titers were not significantly different between the two groups receiving inactivated vaccines (P = 0.86). Our results indicated that 28% of the population vaccinated with Covaxin and 32% of people vaccinated with BBIBP-CorV showed no response to the vaccine. There was also a statistically insignificant difference between age, BMI, and gender with antibody level in each group of vaccines (P > 0.05). Conclusion: Based on a limited population data , our study showed that the viral vector-based vaccines produced higher levels of neutralized antibodies than the inactivated vaccines, and their rate of non-response was lesser.
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.